A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
At a glance
- Drugs PF 6412562 (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions
- 14 Feb 2019 Planned End Date changed from 31 Dec 2018 to 31 Mar 2019.
- 14 Feb 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2019.
- 19 Sep 2018 New trial record